European responses to the Ebola crisis- Part I: Initiatives at the European Medicines Agency (EMA)

Research output: Other contributionNet publication - Internet publicationResearch

While it is evident that the current Ebola crisis requires both immediate responses and more sustainable changes in health care policy, research and regulation, medicines regulators are collaborating internationally to find innovative solutions for enhancing the evaluation of and access to potential new medicines to counter Ebola outbreaks. In a statement announced by the International Coalition of Medicines Regulatory Authorities (ICMRA) in September 2014, regulators around the world led by the FDA and the EMA have vowed to collaborate in supporting accelerated evaluation of experimental new drugs to treat Ebola virus infections and say they will encourage submission of regulatory dossiers. This clearly backs up the World Health Organization’s (WHO) decision to test experimental Ebola treatments in infected patients in the current outbreak region in West Africa and to speed up the development of vaccines.

In part 1 of this blog-series I summarize and discuss some of the recent European responses to the current crisis starting with an overview on recent initiatives at the EMA.
Original languageEnglish
Publication date12 Nov 2014
Publication statusPublished - 12 Nov 2014

    Research areas

  • Faculty of Law - Ebola, legal and regulatory responses challenges, global responses

ID: 127237528